Blue-light filtering IOLs

Article

Making driving safer in glare conditions

When driving in high-glare conditions the visibilities of objects are reduced, and lowcontrast objects may be rendered invisible. A major cause of the problems associated with glare is that light is scattered within the eye onto the retina (veiling glare) thus reducing the contrast of the retinal image. This reduction of contrast is called disability glare.

Study design

The main indicator of driving safety that was used was the safety margin at the point when the driver initiated the turn. This safety margin can be thought of as the amount of time that would be leftover if the driver made the turn: a safety margin of +2 seconds means that the driver could finish their turn and leave the intersection 2 seconds before the oncoming car entered the same intersection (a safe situation) while a safety margin of 0 seconds means the back bumper of the driver's car would clear the intersection at the exact instant the oncoming vehicles' front bumper entered the intersection (a very unsafe situation). A smaller safety margin in this context increases the likelihood of a collision with the oncoming vehicle. Of particular interest was whether the safety margin used by drivers for turns changed in the presence of glare and whether this change was effected by the used of blue-light filtering IOLs.

Across the two studies a total of 67 patients (mean age of 72 years) previously implanted with IOLs developed by Alcon Laboratories were evaluated. There were two blue light-filtering groups: 17 patients implanted with blue-light filtering, acrylic IOLs (AcrySof Model SA60AT) and 18 patients implanted with blue-light filtering, toric IOLs (AcrySof Models SN6ATT or SN60TT). The control groups (a total of 32 patients) were implanted with IOLs without UVonly filtering (AcrySof Model SA60AT).

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.